Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Apr;40(4):941–946. doi: 10.1128/aac.40.4.941

Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains.

E Azoulay-Dupuis 1, P Moine 1, J P Bedos 1, V Rieux 1, E Vallee 1
PMCID: PMC163235  PMID: 8849256

Abstract

We used a mouse model of pneumococcal pneumonia to assess the bactericidal effect of increasing doses of amoxicillin (AMX) against clinical strains with various susceptibilities to penicillin. Twelve strains that exhibited similar virulence in mice were selected. Three were penicillin susceptible (PS) (penicillin and AMX MICs = 0.01 to 0.03 microgram/ml), three were intermediately resistant (PIR) (penicillin and AMX MICs = 0.5 to 1 microgram/ml), and six were penicillin resistant (PR) (penicillin and AMX MICs = 1 to 8 micrograms/ml). Leukopenic Swiss mice were infected intratracheally with 10(7) CFU of each strain. Treatment was initiated 3 h after infection and consisted of a single subcutaneous injection of AMX at doses ranging from 2.5 to 10 mg/kg (PS strains), 5 to 100 (PIR strains), and 25 to 3,000 (PR strains). Bacterial killing kinetics were recorded in the lungs over 9 h. The maximal log CFU reduction (Emax) was observed 3 h postinjection. The relation between Emax and log10(dose/MIC) showed two populations. With seven strains (the three PS, the three PIR, and one of the six PR [MICs, penicillin/AMX = 4/1]) a good correlation was observed between Emax and log10(dose/MIC) (r = 0.772; P < 0.02). A bactericidal effect equal to 3.5 log10 CFU was observed at a log10(dose/MIC) = 2. At this ratio, with the five other PR strains, Emax varied from 0.4 to 1.6 log10 CFU. In brain heart infusion medium containing AMX at 50 times the relevant MIC, these five PR strains were tolerant in vitro. Treatment failure with AMX was found in vivo, with tolerant, highly resistant strains.

Full Text

The Full Text of this article is available as a PDF (246.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azoulay-Dupuis E., Bedos J. P., Vallée E., Hardy D. J., Swanson R. N., Pocidalo J. J. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis. 1991 Feb;163(2):319–324. doi: 10.1093/infdis/163.2.319. [DOI] [PubMed] [Google Scholar]
  2. Briles D. E., Crain M. J., Gray B. M., Forman C., Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun. 1992 Jan;60(1):111–116. doi: 10.1128/iai.60.1.111-116.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bédos J. P., Rolin O., Bouanchaud D. H., Pocidalo J. J. Relation entre virulence et résistance aux antibiotiques des pneumocoques. Apport des donnée expérimentales sur un modèle animal. Pathol Biol (Paris) 1991 Dec;39(10):984–990. [PubMed] [Google Scholar]
  4. Handwerger S., Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis. 1985 May-Jun;7(3):368–386. doi: 10.1093/clinids/7.3.368. [DOI] [PubMed] [Google Scholar]
  5. Jabes D., Tomasz A. Lytic and bactericidal activity of FCE 22101. J Antimicrob Chemother. 1989 Mar;23 (Suppl 100):75–83. doi: 10.1093/jac/23.suppl_c.75. [DOI] [PubMed] [Google Scholar]
  6. Liu H. H., Tomasz A. Penicillin tolerance in multiply drug-resistant natural isolates of Streptococcus pneumoniae. J Infect Dis. 1985 Aug;152(2):365–372. doi: 10.1093/infdis/152.2.365. [DOI] [PubMed] [Google Scholar]
  7. Moine P., Vallée E., Azoulay-Dupuis E., Bourget P., Bédos J. P., Bauchet J., Pocidalo J. J. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother. 1994 Sep;38(9):1953–1958. doi: 10.1128/aac.38.9.1953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Moreillon P., Markiewicz Z., Nachman S., Tomasz A. Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob Agents Chemother. 1990 Jan;34(1):33–39. doi: 10.1128/aac.34.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Moreillon P., Tomasz A. Penicillin resistance and defective lysis in clinical isolates of pneumococci: evidence for two kinds of antibiotic pressure operating in the clinical environment. J Infect Dis. 1988 Jun;157(6):1150–1157. doi: 10.1093/infdis/157.6.1150. [DOI] [PubMed] [Google Scholar]
  10. Morrison D. A., Trombe M. C., Hayden M. K., Waszak G. A., Chen J. D. Isolation of transformation-deficient Streptococcus pneumoniae mutants defective in control of competence, using insertion-duplication mutagenesis with the erythromycin resistance determinant of pAM beta 1. J Bacteriol. 1984 Sep;159(3):870–876. doi: 10.1128/jb.159.3.870-876.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tomasz A., Moreillon P., Pozzi G. Insertional inactivation of the major autolysin gene of Streptococcus pneumoniae. J Bacteriol. 1988 Dec;170(12):5931–5934. doi: 10.1128/jb.170.12.5931-5934.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Trombe M. C., Clavé C., Manias J. M. Calcium regulation of growth and differentiation in Streptococcus pneumoniae. J Gen Microbiol. 1992 Jan;138(1):77–84. doi: 10.1099/00221287-138-1-77. [DOI] [PubMed] [Google Scholar]
  13. Tuomanen E., Durack D. T., Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother. 1986 Oct;30(4):521–527. doi: 10.1128/aac.30.4.521. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES